Funding for this research was provided by:
Stiftelsen Dam (2019/FO249324)
The Norwegian National Advisory Unit on Rare Disorders (Project No 226038, No 226053)
Received: 5 March 2022
Accepted: 12 February 2023
First Online: 22 February 2023
: The study was approved by the Regional Committee for Medical and Health Research Ethics (REK) South–East, Norway (Approval Number 2016/2271), and is registered on ClinicalTrials.gov (NCT03780153). The UK Biobank study was approved by the North West Multicenter Research Ethics Committee, UK (project ID 6569). All participants gave their informed, written consent prior to participation. The study has been conducted in accordance with the STROBE guidelines for the reporting of observational studies.
: All authors read and approved the final manuscript.
: JL, ODL, MP and PW are employees of AMRA Medical AB. JL, PW and ODL are stockholders of AMRA Medical AB. The other authors have completed the ICMJE form and declare that they have no competing interests.